Patents by Inventor Jason W. Dodson

Jason W. Dodson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYTOTOXICITY TARGETING CHIMERAS
    Publication number: 20250136722
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
    Type: Application
    Filed: August 12, 2022
    Publication date: May 1, 2025
    Inventors: Peiling CHEN, Michael Gerard DARCY, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Andrew Peter MARCUS, Joseph Paul MARINO, Jeffrey Alan OPLINGER, James P. PHELAN, Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG, Jae U. JEONG
  • CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS
    Publication number: 20250057958
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
    Type: Application
    Filed: August 13, 2024
    Publication date: February 20, 2025
    Inventors: Peiling Chen, Michael Gerard Darcy, Jason W. Dodson, Beth Anne Knapp-Reed, Joseph Paul Marino, JR., Jeffrey Alan Oplinger, Matthew Robert Sender, Brandon James Turunen, Guosen Ye, Cunyu Zhang
  • CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS
    Publication number: 20240325392
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
    Type: Application
    Filed: February 9, 2024
    Publication date: October 3, 2024
    Inventors: Peiling CHEN, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Joseph Paul MARINO, JR., Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG
  • Heterocyclic amides useful as protein modulators
    Patent number: 11970480
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: April 30, 2024
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
  • Heterocyclic Amides Useful as Protein Modulators
    Publication number: 20230071675
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Application
    Filed: May 17, 2022
    Publication date: March 9, 2023
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth CHARNLEY, Michael G DARCY, Jason W. DODSON, Xiaoyang DONG, Terry V. HUGHES, Jianxing KANG, Lara LEISTER, Yiqian LIAN, Yue LI, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
  • HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20210238172
    Abstract: The invention relates to combinations comprising a compound of the formula: or a salt thereof; and one or more additional pharmaceutically agents active against HIV, and methods of using the same.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 5, 2021
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Adam Kenneth CHARNLEY, Michael Gerard DARCY, Jason W. DODSON, Xiaoyang DONG, David FAVRE, Terry Vincent HUGHES, Jianxing KANG, Lara Kathryn LEISTER, Yuehu LI, Yiqian LIAN, John F. MEHLMANN, Neysa NEVINS, Joshi M. RAMANJULU, Joseph J. ROMANO, Gren Z. WANG, Guosen YE, Daohua ZHANG
  • Heterocyclic amides useful as protein modulators
    Patent number: 10975287
    Abstract: Disclosed are compounds having the formula: wherein Ra, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 13, 2021
    Inventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Terry V. Hughes, Yue Li, Yiqian Lian, Neysa Nevins, Joshi M. Ramanjulu